Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Krejci, Marta
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. [electronic resource] - Clinical lymphoma & myeloma Dec 2009 - 436-42 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1938-0712
10.3816/CLM.2009.n.086 doi
Adult
Aged
Boronic Acids--therapeutic use
Bortezomib
Disease Progression
Hematopoietic Stem Cell Transplantation
Humans
Middle Aged
Multiple Myeloma--mortality
Pyrazines--therapeutic use
Recurrence
Thalidomide--therapeutic use
Transplantation, Autologous
Treatment Outcome
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. [electronic resource] - Clinical lymphoma & myeloma Dec 2009 - 436-42 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1938-0712
10.3816/CLM.2009.n.086 doi
Adult
Aged
Boronic Acids--therapeutic use
Bortezomib
Disease Progression
Hematopoietic Stem Cell Transplantation
Humans
Middle Aged
Multiple Myeloma--mortality
Pyrazines--therapeutic use
Recurrence
Thalidomide--therapeutic use
Transplantation, Autologous
Treatment Outcome